Rhizen Pharmaceuticals SA - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Rhizen Pharmaceuticals SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Rhizen Pharmaceuticals SA - Product Pipeline Review - 2014', provides an overview of the Rhizen Pharmaceuticals SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rhizen Pharmaceuticals SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Rhizen Pharmaceuticals SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Rhizen Pharmaceuticals SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Rhizen Pharmaceuticals SA's pipeline products

Reasons to buy

- Evaluate Rhizen Pharmaceuticals SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Rhizen Pharmaceuticals SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Rhizen Pharmaceuticals SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Rhizen Pharmaceuticals SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rhizen Pharmaceuticals SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Rhizen Pharmaceuticals SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Rhizen Pharmaceuticals SA Snapshot 5
Rhizen Pharmaceuticals SA Overview 5
Key Information 5
Key Facts 5
Rhizen Pharmaceuticals SA - Research and Development Overview 6
Key Therapeutic Areas 6
Rhizen Pharmaceuticals SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Rhizen Pharmaceuticals SA - Pipeline Products Glance 11
Rhizen Pharmaceuticals SA - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Rhizen Pharmaceuticals SA - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Rhizen Pharmaceuticals SA - Drug Profiles 13
RP-6530 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
TGR-1202 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
RP-3128 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
RP-6503 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecule to Agonize GPR-119 for Diabetes 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecules to Inhibit C-Met for Solid Tumor 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Rhizen Pharmaceuticals SA - Pipeline Analysis 19
Rhizen Pharmaceuticals SA - Pipeline Products by Target 19
Rhizen Pharmaceuticals SA - Pipeline Products by Route of Administration 20
Rhizen Pharmaceuticals SA - Pipeline Products by Molecule Type 21
Rhizen Pharmaceuticals SA - Pipeline Products by Mechanism of Action 22
Rhizen Pharmaceuticals SA - Recent Pipeline Updates 23
Rhizen Pharmaceuticals SA - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables
Rhizen Pharmaceuticals SA, Key Information 5
Rhizen Pharmaceuticals SA, Key Facts 5
Rhizen Pharmaceuticals SA - Pipeline by Indication, 2014 8
Rhizen Pharmaceuticals SA - Pipeline by Stage of Development, 2014 9
Rhizen Pharmaceuticals SA - Monotherapy Products in Pipeline, 2014 10
Rhizen Pharmaceuticals SA - Phase I, 2014 11
Rhizen Pharmaceuticals SA - Preclinical, 2014 12
Rhizen Pharmaceuticals SA - Pipeline by Target, 2014 19
Rhizen Pharmaceuticals SA - Pipeline by Route of Administration, 2014 20
Rhizen Pharmaceuticals SA - Pipeline by Molecule Type, 2014 21
Rhizen Pharmaceuticals SA - Pipeline Products by Mechanism of Action, 2014 22
Rhizen Pharmaceuticals SA - Recent Pipeline Updates, 2014 23